ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.…
ImageneBio Reports Third Quarter 2026 Financial Results
ImageneBio (NASDAQ: IMA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 18 employees.
The shares were at 3.920 USD on 20 November 2026, down 52.7% over 52 weeks. Its 52-week range is 3.005 USD to 8.840 USD: the price is 55.7% below the high and 30.4% above the low.
Its market capitalisation is 48.83M USD.
ImageneBio reports return on equity of -34.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 134.24M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.